Regeneron, Alnylam win FDA nod for myasthenia gravis therapy

Regeneron and Alnylam received FDA approval for Livsayis (cemdisiran), an RNA therapy for myasthenia gravis in adults. The drug was jointly developed by the two companies.

Original reporting
Published Nov 19, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy — source image
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

A regulatory approval is a discrete catalyst that can change valuation assumptions for both the primary developer and the platform partner, even without revenue guidance in the excerpt.

02

Market read

Traders may adjust biotech exposure and relative positioning in RNAi names based on the new FDA-approved product catalyst.

03

What to watch

The article excerpt omits label details, launch timeline, and any financial terms of the REGN-ALNY collaboration, which can materially affect how much incremental value is actually realized.

Relevance 7/10Novelty 4/10Timing: today’s FDA approval news

Background

The FDA approval covers Livsayis (cemdisiran), an RNA therapeutic for adults with myasthenia gravis, developed with Alnylam’s involvement.

Company-level read

Ticker impact

$REGNBullishMedium confidence
Context

Regeneron received U.S. approval for Livsayis (cemdisiran), an RNA therapeutic for adults with myasthenia gravis, signaling a new commercial product.

Expected impact

Likely positive repricing as the market adds probability-weighted sales from a newly approved myasthenia gravis therapy.

Evidence & confidence

The article states a direct regulatory approval event for REGN’s product, which is typically material for biotech valuation even without financial guidance details.

$ALNYBullishMedium confidence
Context

Alnylam is named as the developer partner for Livsayis (cemdisiran), which the FDA approved for myasthenia gravis treatment.

Expected impact

Likely upward bias as investors price in improved platform validation and potential partner economics.

Evidence & confidence

The text links ALNY to the approved RNA therapeutic, but provides no explicit financial terms, limiting precision on magnitude.

Market effects

Reinforces investor appetite for RNAi therapeutics and can lift sentiment across the small group of RNA platform developers and partners.

Primarily US biotech sentiment, with potential spillover to global biotech peers trading on FDA approval momentum.

Supports the broader global narrative that RNA therapeutics are progressing through late-stage regulatory milestones.

Counterpoint

Approval headlines can fade if uptake, pricing, or competitive positioning are unclear; without launch timing and commercial data, the market may already be partially positioned.

Key entities

  • Regeneron Pharmaceuticals

    Received U.S. approval for Livsayis (cemdisiran) for adults with myasthenia gravis.

  • Alnylam Pharmaceuticals

    Partnered in developing the RNA therapeutic Livsayis (cemdisiran) that received FDA approval.

  • Livsayis (cemdisiran)

    RNA therapeutic approved by the FDA for adults with myasthenia gravis.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.